Joanna Opalinska

Providence College — United States

Medicine · Health Sciences

24h-index3.6kcitations89works3.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(52), Protein Degradation and Inhibitors(21), Monoclonal and Polyclonal Antibodies Research(16), Acute Myeloid Leukemia Research(12), RNA Interference and Gene Delivery(11)

Publications89 total

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change
Blood·2025Open Access
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials
Blood Advances·2025· 4 citedOpen Access
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
The Lancet Haematology·2025· 2 cited
DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.
Journal of Clinical Oncology·2025· 1 cited
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Blood Cancer Journal·2025· 1 citedOpen Access
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Blood Cancer Journal·2025· 10 citedOpen Access
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
Blood·2024· 5 cited
Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial
Blood·2024· 2 citedOpen Access
P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2024· 2 cited
OA-13 Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
MM-557 DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2024· 2 cited
Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2024
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2024· 1 cited
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2024· 3 cited
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2024· 20 cited
Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a
Blood·2023· 2 citedOpen Access
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial
Cancer·2023· 52 citedOpen Access
P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
HemaSphere·2023· 2 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Suzanne Trudel(12), Rakesh Popat(12), Ira Gupta(11), Paul G. Richardson(10), Sagar Lonial(9), Adam D. Cohen(9), Ajay K. Nooka(8), Natalie S. Callander(7), Edward N. Libby(7), Li Zhou(7), Davendra Sohal(7), Amit Verma(7), Ashraf Badros(6), Douglas W. Sborov(6), Peter M. Voorhees(6), Axel Hoos(6), Roxanne C. Jewell(6), Alan M. Gewirtz(6), John M. Greally(6), Nikoletta Lendvai(5)